CClinicalTrials.gg
CompletedNCT02820337ObéVIHUpdated Feb 2, 2024

Pathophysiological Study of Adipose Tissue of Patients Infected With HIV

An observational study in HIV, sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-02-02.

Sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main goal of our project is the study of subcutaneous and visceral (SAT and VAT) adipose tissue taken during bariatric surgery (Single port sleeve gastrectomy) of subjects with HIV infection, anf morbid obesity with undetectable viral load (VL) and having HIV lipohypertrophy particularly truncal. The study covers both the morphology of adipocytes,fibrosis, immune activation and inflammation, gene expression, pharmacology of antiretroviral drugs (ARV) and the measurement of viral replication in the adipose tissue and the plasma before and after bariatric surgery.

Read the detailed description

The choice of the sleeve gastrectomy is based on choosing an effective technique with few complications, no rupture of digestive continuity and therefore little malabsorptive effect with a better quality of life.

The intervention of sleeve gastrectomy offers a unique opportunity to study the SAT and VAT of HIV obese patients before and after bariatric surgery, to analyze the specific modifications of this tissue and to better understand the pathophysiology of this disease. The term associated with changes in cardiometabolic comorbidities and their improvement after weight loss will be important elements in the management of these patients. It is therefore important to evaluate whether the fibrosis term changes observed in HIV patients will change the effectiveness of the intervention.

In the general population, obesity is a major public health problem. It is considered an inflammatory disease, multifactorial with chronic evolution, which requires long-term medical care and / or surgery . Indeed, the body mass index (BMI) correlates with increased mortality mainly due to cardiovascular diseases (hypertension, coronary artery disease), cancer and diabetes. Finally, overweight and obesity are the leading causes of liver disease in Western countries resulting in nonalcoholic fatty liver disease, a term that includes all the hepatic lesions observed in overweight and obesity: steatosis, steatohepatitis, fibrosis, cirrhosis or hepatocellular carcinoma. Nonalcoholic fatty liver disease reflects not only the presence of insulin resistance but also participates in its installation. Reducing overweight is therefore a key part of treatment to reduce chronic inflammation, insulin resistance and liver damage.

There is little data in the literature on the prevalence of obesity in the population of HIV patients. In France, the prevalence of obesity in the French Hospital Database on HIV is 15.1% among women and 5.3% among men, similar to prevalence in the general population. Patients born in sub-Saharan Africa have a higher risk with 20.7% versus 12.2% in women and 10.9% versus 4.7% for men.

No data is available on the obesity complications described in the general population in our population of obese HIV patients. Nevertheless, apart from obesity, patients infected with HIV develop cardiovascular and metabolic complications well documented in recent years.

French and international recommendations agree that the management of obesity should be multidisciplinary. In the treatment, surgical treatment is the treatment of choice in French and international recommendations in the following indications:

  • morbid obesity (BMI ≥ 40 kg / M²) resistant to medical treatment and exposing patients to serious complications that can not be controlled by the specific treatment
  • obesity with BMI between 35 and 40 kg / M² with comorbidities associated with life-threatening or functional outcomes: cardiovascular disease, musculoskeletal disease, severe metabolic disorders not controlled by maximal medical therapy. In each case, the indication can be considered in patients who have had access to specialized medical care for at least 6 months, also including complementary approaches (diet, physical activity, management of psychological problems, treatment complications).

At present, the sleeve gastrectomy is the technique of choice in the general population with, compared to other bariatric surgery techniques such as bypass, reducing complications, length of hospital stay, operative time, a gain in term quality of life without disruption of digestive continuity and therefore little or no malabsorption. This lack of malabsorption it an argument of choice in our HIV patients on cART with a reduced risk of malabsorption of ARV and vitamin deficiencies such as vitamin D deficiency already well described in HIV. The minimally invasive approach (1 trocar), routinely performed by Dr. G. Pourcher for obese patients whether they are infected with HIV, reduces surgical risk. This Single port also allows easy access to SAT, VAT and liver.

The management of obesity in the HIV population, now having a similar life expectancy should be the same as that of the general population but remains to this day very marginal. The literature on the subject is almost "poor" Additionally, comorbid conditions existing in the population of HIV patients are a target population requiring support at least equivalent to that of the general population.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida is the lead sponsor of 19 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Pathophysiology of adipose tissue of obese HIV-infected patients undergoing a sleeve gastrectomy using single port.

20 patients will be required. Patients will be included after positive opinion of the multidisciplinary meeting of management of obesity.

Inclusion criteria

  • Documented HIV-1 infection,
  • Aged to 18 at 65 ans,
  • Obesity defined as a Body Mass Index (BMI)> 35 kg / M² with comorbidities Or BMI > 40 kg/M²
  • Forget bariatric surgery after a positive opinion of the specialized multidisciplinary meeting
  • on stable antiretroviral therapy for 12 months
  • with controlled HIV infection (\<50 copies / ml)
  • Signed informed consent
  • Karnofsky Index > 80 %
  • Patient affiliated or beneficiary of a national insurance scheme (article L1121-11 of the Public health code) (the Medical aid of State or SOUL is not a national insurance scheme)

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled severe infection
  • Current pregnancy (positive HCG)
  • Saving justice, guardianship
  • Participation to another study.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
20 participants (actual)
Patient registry
No

Groups and cohorts

  • non comparative

    Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal

06

What researchers measure

Primary outcomes

  1. Measure of fibrotest to assess the liver fibrosis

    fibrotest is the estimated index of liver fibrosis established according to the assay values of 5 parameters: alpha-2 macroglobulin, haptoglobin, apolipoprotein-A1, total bilirubin and g-glutamyl-transpeptidase.

    Time frame: 30 months

  2. Measure of actitest to assess the liver inflammation

    ActiTest gives an estimate of the intensity of the inflammation and liver cell killing activity. ActiTest uses 5 markers fibrotest which is added the dosage of transaminases measure of Ambulatory blood pressure.

    Time frame: 30 months

  3. Measure of steatotest to assess the liver steatosis

    Time frame: 30 months

  4. Measure of serum inflammatory biomarkers assessed by ELISA assay

    Time frame: 30 months

  5. Measure of viral load in plasma and adipose tissue assessed by quantification using Cobas 6800 system/cobas HIV-1 Test (Roche)

    Time frame: 30 months

  6. Measure of the pharmacokinetics of antiretrovirals by estimating trough plasma concentrations using mass spectrometry assay.

    Time frame: 30 months

  7. Measure of the pharmacokinetics of antiretrovirals by estimating trough adipose tissue concentrations using mass spectrometry assay.

    Time frame: 30 months

Secondary outcomes

  1. Measure of left ventricular mass assessed by echocardiography to evaluate cardiovascular function

    Time frame: 30 months

  2. Measure of Volume of epicardial fat assessed by echocardiography to evaluate cardiovascular function

    Time frame: 30 months

  3. Carotid intima media thickness assessed by echo-doppler to evaluate cardiovascular atherosclerosis

    Time frame: 30 months

  4. Score of calcification assessed by cardiac CT to evaluate cardiovascular atherosclerosis

    Time frame: 30 months

  5. Measure of body composition assessed by dexascan to evaluate the impact of sleeve gastrectomy

    Time frame: 30 months

  6. Measure of the surface of the adipose tissue subcutaneous and visceral assessed by tomodensitometry to evaluate the impact of sleeve gastrectomy

    Time frame: 30 months

  7. Measure of bone mineral density assessed by dexascan to evaluate the impact of sleeve gastrectomy

    Time frame: 30 months

07

Study locations

1 site
  • Yasmine Dudoit
    Paris, 75013, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02820337
Lead sponsor
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Responsible party
Sponsor
First posted
Jun 30, 2016
Start date
Jul 2016
Primary completion
Dec 2022
Completion
Dec 15, 2023
Last update
Feb 2, 2024

Study contacts

Valérie POURCHER MARTINEZ, MD, PhD
principal investigator · Groupe Hospitalier Pitié-Salpêtrière

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion